ClinicalTrials.gg
Active, not recruitingNCT05096182Updated Sep 25, 2026

Long-Term Follow-up of Patients With Chronic Kidney Disease Treated With Cellgram-CKD

An observational study in Chronic Kidney Disease, sponsored by Pharmicell Co., Ltd.. Active, not recruiting at 1 site in South Korea. Open to participants aged 19 Years to 79 Years. Per ClinicalTrials.gov, last updated 2026-09-25.

Sponsored by Pharmicell Co., Ltd. · Observational

How we know

Updated Sep 25, 2026Title changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
10
Ages
19 Years to 79 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 124 studies in Renal Insufficiency, Chronic with a site in Korea, Republic of — 18 open to participants now, 30 under way, 17 of them phase 3. Renal Insufficiency, Chronic · Korea, Republic of.

Enrollment
23rd of 23
10 · median 748
Started
2022
with 11 others
Observational
23 of 124
4 open now
Primary completion
2027-03
later than 9 of 29 live
Registered
79th of 124
by date

Among the 124 studies in Renal Insufficiency, Chronic with a site in Korea, Republic of, this one is the 23rd largest by enrollment of the 23 observational ones that give a count, is one of 12 that started in 2022, is one of 23 observational ones, reaches primary completion later than 9 of the 29 other live ones, and was the 79th registered.

Renal Insufficiency, Chronic

3,098 studies on the registry are indexed under Renal Insufficiency, Chronic; 700 are open to participants now.

Browse Renal Insufficiency, Chronic studies →

Open to participants now

18 of the 124 studies in Renal Insufficiency, Chronic with a site in Korea, Republic of are open now. Recruiting first, the newest first:

13 more — sign in →

All 18 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 434 Renal Insufficiency, Chronic studies recruiting now, 245 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 43 take children under 18; 80 take healthy volunteers.

This study: 19 Years to 79 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 124 studies in Renal Insufficiency, Chronic with a site in Korea, Republic of, or all of them as a file.
02

Study summary

This long-term follow-up study is a 5-year long-term follow-up study to evaluate long-term safety in Cellgram-CKD subjects. (refer to ClinicalTrials.gov. Identifier: NCT05042206).

Read the detailed description

This long-term follow-up study is a 5-year long-term follow-up study to evaluate long-term safety in Cellgram-CKD subjects. (refer to ClinicalTrials.gov.Identifier: NCT05042206).

The long-term safety of Cellgram-CKD is evaluated by monitoring whether or not an adverse event of special interest (AESI) occurs for 5 years from the date of administration in Cellgram-CKD subjects who voluntarily consented in writing to participate in the long-term follow-up study.

03

Conditions studied

  • Chronic Kidney Disease
04

Who can participate

Ages eligible
19 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with chronic kidney disease who participated in the PMC-P-12 clinical trial, among those who received Cellgram-CKD, those who agreed to participate in this long-term follow-up study

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Those who participated in the PMC-P-12 clinical trial and received Cellgram-CKD
  • Subjects who consented in writing to this long-term follow-up study

Exclusion criteria

Exclusion Criteria:

  • Not Applicable
05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
10 participants (actual)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Observe the occurrence of Adverse Event of Special Interest (AESI).

    AESI stands for Serious Adverse Event as follows. 1. death 2. Creation of neoplasms or malignancies in tissues or organs 3. The development of an immune response, including the exacerbation or new development of a previous autoimmune disease 4. Occurrence of Other delayed adverse events related to stem cell therapy

    Time frame: 5 years from the date of administration of Cellgram-CKD

07

Study locations

1 site
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2022 (actual). Primary completion is estimated for Mar 2027, 60 months after the start.

Of 51 industry-sponsored observational studies under Renal Insufficiency, Chronic, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 51. This study's planned 60 months is above that.

Counting every sponsor, half of 327 studies reached it within 45 months; a quarter within 22 and three quarters within 191.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 15, 2021
First posted
Oct 27, 2021
StartActual
Mar 10, 2022
Primary completionEst.
Mar 2027
CompletionEst.
Mar 2027
Last update
Sep 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Title
Long-termTerm Follow-up of Patients With Chronic Kidney Disease Who Had AdministeredTreated With Cellgram-CKD in PMC-P-12 Study
Sep 25, 2026
Show all 1 update
  1. Sep 25, 2026
    Title Long-termTerm Follow-up of Patients With Chronic Kidney Disease Who Had AdministeredTreated With Cellgram-CKD in PMC-P-12 Study
    + 5 other changes: verification date, description, conditions, site details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT05096182
Lead sponsor
Pharmicell Co., Ltd.
Responsible party
Sponsor
First posted
Oct 27, 2021
Start date
Mar 10, 2022
Primary completion
Mar 2027 (estimated)
Completion
Mar 2027 (estimated)
Last update
Sep 25, 2026

Study contacts

Hyosang Kim
principal investigator · Asan Medical Center Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion